Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesEW +0.25%97 Cash Ratio is 2.61 as of Mar. 2026, which is 66% above its 10-year median of 1.57. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.84 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 74.67% on this metric.
Edwards Lifesciences has a Cash Ratio of 2.61. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Edwards Lifesciences's Cash Ratio or its related term are showing as below:
EW'
s Cash Ratio Range Over the Past 10 Years
Min: 0.94 Med: 1.57 Max: 2.89
Current: 2.61
During the past 13 years, Edwards Lifesciences's highest Cash Ratio was 2.89. The lowest was 0.94. And the median was 1.57.
EW's Cash Ratio is ranked better than 74.67% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs EW: 2.61
Edwards Lifesciences (NYSE:EW) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Edwards Lifesciences Cash Ratio Related Terms
Edwards Lifesciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (EW) has a Cash Ratio of 2.61 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Edwards Lifesciences and its competitors. This is 66% above median its historical median of 1.57. Over the past decade, Edwards Lifesciences' Cash Ratio has ranged from 0.94 to 2.89. According to the industry distribution chart, Edwards Lifesciences ranks #213 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 25.3%.
Is Edwards Lifesciences' Cash Ratio too high?
Edwards Lifesciences' current Cash Ratio of 2.61 is 66% above median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 2.89. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Edwards Lifesciences' value of 2.61 is 169.1% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #213 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Cash Ratio compare to BSX and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #213 out of 841 companies for Cash Ratio. This puts Edwards Lifesciences in the upper half of its industry. The industry median Cash Ratio is 0.97. Edwards Lifesciences' value of 2.61 is 169.1% above this benchmark. Historically, Edwards Lifesciences' own Cash Ratio has ranged from 0.94 to 2.89 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 0.97, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Cash Ratio of 2.61 is 169.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Cash Ratio is 2.61, which is 66% above median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Modestly Undervalued. The stock's GF Value™ is $93.84, compared to a current price of $84.76 — trading 9.7% below its estimated fair value. The current Cash Ratio is 2.61, which is 66% above median its 10-year median of 1.57 and 169.1% above the Medical Devices & Instruments industry median of 0.97. Edwards Lifesciences' overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Cash Ratio is 2.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $84.76 is trading 9.7% below its estimated GF Value™ of $93.84.
GuruFocus considers Edwards Lifesciences to be Modestly Undervalued.
Key valuation signals for EW:
Cash Ratio: 2.61 (66% above median its 10-year median of 1.57)
GF Value™: $93.84 vs. price of $84.76 (9.7% below fair value)
Industry Position: 169.1% above the Medical Devices & Instruments median (#213 of 841)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for EW
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
